KRAS and non-small cell lung carcinoma: In 2021, a further breakthrough occurred when the Kirsten rat sarcoma virus (KRAS) inhibitor sotorasib was approved for the treatment of locally advanced or metastatic KRAS-G12C mutant NSCLC.